Jubilant Life Sciences Ltd.

Quarterly Financials

The company has invested heavily in R&D past couple of years and is able to grow the revenue on new approvals . There is strength of revenue growth on YoY & QoQ basis . This March we expect YoY to show good growth but QoQ to remain flat.

May 3rd, 2018

Debt /Equity: 1.18x

Mutual Fund Holding Since Last Quarter : SAME

FII Holding Since Last Quarter : UP

New Investor : Rakesh R Jhunjhunwala : 1.26%

The company has received many approval in past 6 months which are showing in revenue growth , we believe this would drive the company profitability higher and Rupee depreciation would help the exports support.

Recommendation : BUY

Buying Price Limit Till : Rs. 850

Portfolio Allocation : 2%